

**FRAXA Research Foundation, Inc.**

**Financial Statements  
December 31, 2024**

**FRAXA Research Foundation, Inc.**

Contents  
December 31, 2024

	<u>Page</u>
Independent Auditor's Report	1-2
Statement of Financial Position	3
Statement of Activities	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to Financial Statements	7-11



**FRITZ DEGUGLIELMO LLC**  
**CERTIFIED PUBLIC ACCOUNTANTS**  
**& BUSINESS ADVISORS**

**INDEPENDENT AUDITOR'S REPORT**

To the Board of Directors of  
FRAXA Research Foundation, Inc.

We have audited the accompanying financial statements of FRAXA Research Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of December 31, 2024, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of FRAXA Research Foundation, Inc. as of December 31, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

***Basis for Opinion***

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of FRAXA Research Foundation, Inc., and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

***Responsibilities of Management for the Financial Statements***

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about FRAXA Research Foundation, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

***Auditor's Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of FRAXA Research Foundation Inc.'s internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about FRAXA Research Foundation Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Certified Public Accountants

A handwritten signature in blue ink, appearing to read "Fitch", followed by a stylized flourish.

Newburyport, Massachusetts

August 5, 2025

**FRAXA Research Foundation, Inc.**

## Statement of Financial Position

December 31, 2024

## ASSETS

## Current Assets

Cash and Cash Equivalents	\$ 2,434,956
Certificates of Deposit	688,866
Investments	1,790,112
Pledges Receivable	<u>50,311</u>
Total Current Assets	<u>4,964,245</u>

Total Assets	<u>\$ 4,964,245</u>
--------------	---------------------

## LIABILITIES AND NET ASSETS

## Current Liabilities

Accounts Payable and Accrued Expenses	\$ <u>12,770</u>
Total Current Liabilities	<u>12,770</u>

Total Liabilities	<u>12,770</u>
-------------------	---------------

## Net Assets

Without Donor Restrictions	4,755,387
With Donor Restrictions	<u>196,088</u>

Total Net Assets	<u>4,951,475</u>
------------------	------------------

Total Liabilities and Net Assets	<u>\$ 4,964,245</u>
----------------------------------	---------------------

See accompanying notes to financial statements and independent auditor's report.

**FRAXA Research Foundation, Inc.**  
Statement of Activities  
For the year ended December 31, 2024

	<u>Without Donor</u> <u>Restrictions</u>	<u>With Donor</u> <u>Restrictions</u>	<u>Total</u>
Revenue and Support			
Contributions and Grants	\$ 1,548,025	\$ 205,792	\$ 1,753,817
In-Kind Contributions	5,256	-	5,256
Fundraising Events	404,123	-	404,123
Other	40,500	-	40,500
Interest and Investment Income, net	113,317	-	113,317
Realized Gain on Investments	2,207	-	2,207
Unrealized Gain on Investments	143,841	-	143,841
Net Assets Released from Restrictions			
Satisfaction of Program Restrictions	<u>9,704</u>	<u>(9,704)</u>	<u>-</u>
Total Revenue and Support	<u>2,266,973</u>	<u>196,088</u>	<u>2,463,061</u>
Expenses			
Research Program	1,164,750	-	1,164,750
Education Program	143,336	-	143,336
Fundraising	78,157	-	78,157
Administration	<u>73,158</u>	<u>-</u>	<u>73,158</u>
Total Expenses	<u>1,459,401</u>	<u>-</u>	<u>1,459,401</u>
Change in Net Assets	807,572	196,088	1,003,660
Net Assets – Beginning of Year	<u>3,947,815</u>	<u>-</u>	<u>3,947,815</u>
Net Assets – End of Year	<u>\$ 4,755,387</u>	<u>\$ 196,088</u>	<u>\$ 4,951,475</u>

See accompanying notes to financial statements and independent auditor's report.

**FRAXA Research Foundation, Inc.**  
Statement of Functional Expenses  
For the year ended December 31, 2024

	Program Services		Total Program Services	Fund- raising	Management and General	Total
	Research	Education				
Grants	\$ 970,350	\$ -	\$ 970,350	\$ -	\$ -	\$ 970,350
Salaries and Wages	155,397	108,456	263,853	30,002	55,626	349,481
Professional Fees	2,478	16,555	19,033	2,271	9,189	30,493
Direct Fundraising	-	-	-	27,824	-	27,824
Payroll Taxes	12,031	6,684	18,715	5,347	2,673	26,735
Employee Benefits	8,666	3,158	11,824	671	2,344	14,839
Registration Fees	4,654	2,586	7,240	2,068	1,034	10,342
Rent	2,970	1,650	4,620	1,320	660	6,600
Printing	2,426	1,348	3,774	1,078	539	5,391
In-Kind Expense	-	-	-	5,256	-	5,256
Office Expense	2,236	1,242	3,478	994	430	4,902
Insurance	1,832	1,018	2,850	814	407	4,071
Postage	546	303	849	243	121	1,213
Telephone	485	270	755	216	108	1,079
Research Expense	500	-	500	-	-	500
Bank and credit fees	133	41	174	33	17	224
Travel	46	25	71	20	10	101
Total Expenses	\$ 1,164,750	\$ 143,336	\$ 1,308,086	\$ 78,157	\$ 73,158	\$ 1,459,401

See accompanying notes to financial statements and independent auditor's report.

**FRAXA Research Foundation, Inc.**  
Statement of Cash Flows  
For the year ended December 31, 2024

Operating Activities

Change in net assets \$ 1,003,660

Adjustments to reconcile change in net assets to  
cash provided by operating activities:

Net unrealized and realized gains on investments (146,048)

Changes in operating assets and liabilities:

Pledges Receivable 11,988

Prepaid Expenses 50,000

Accounts Payable and Accrued Expenses (722)

Net Cash Provided by Operating Activities 918,878

Investing Activities

Proceeds From Sale of Investments 49,040

Purchases of Certificates of Deposit and Investments (251,574)

Net Cash Used in Investing Activities (202,534)

Net increase in cash 716,344

Cash and Cash Equivalents, beginning of year 1,718,612

Cash and Cash Equivalents, end of year \$ 2,434,956

Supplemental Data:

Taxes paid \$ -

Interest paid \$ -

See accompanying notes to financial statements and independent auditor's report.



# **FRAXA Research Foundation, Inc.**

## **Notes to Financial Statements**

**December 31, 2024**

### **NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### **Organization**

FRAXA Research Foundation, Inc. (“FRAXA” or “the Foundation”) was founded in 1994 by three parents of children affected with Fragile X. FRAXA’s mission is to accelerate progress toward effective treatments and ultimately a cure for Fragile X, by directly funding the most promising research through grants and fellowships at universities all over the world.

The Foundation maintains its accounts and prepares its financial statements on the accrual basis of accounting.

#### **Cash and equivalents**

For financial statement purposes, the Foundation considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The cash and cash equivalents balance as of December 31, 2024 was \$2,434,956.

#### **Investments and Certificates of Deposit**

Investments consist of publicly traded equities, mutual funds, debt securities, and certificates of deposit with maturities greater than 3 months. Investments with readily determinable fair values are reported at their fair values in the statement of financial position. Unrealized gains and losses are included in the change in net assets. Investment income and gains restricted by a donor are reported as increases in net assets without donor restrictions if the restrictions are met (either by passage of time or by use) in the reporting period in which the income and gains are recognized. All investments are considered current assets as they can be readily converted into cash as needed.

#### **Pledges Receivable**

The Foundation had \$50,311 of pledges receivable as of December 31, 2024. All of the pledges receivable are collectible within one year. The Foundation has evaluated the pledges receivable and has determined that they are deemed fully collectible as of December 31, 2024. Accordingly, there is no provision for the allowance for doubtful accounts.

#### **Property and Equipment**

Property and equipment with useful lives greater than one year are carried at cost. Equipment is depreciated under the straight-line method using lives between 5 and 7 years. There is no property and equipment reported in these financial statements fitting these criteria.

Expenditures for maintenance and repairs are charged against operations as incurred. Renewals and betterments that materially extend the life of an asset are capitalized.

#### **Grants Payable**

Grants payable are recorded if the Foundation approves a grant but the grant is not paid prior to year-end. As of December 31, 2024, the Foundation had no grants payable outstanding.

#### **Revenue and Revenue Recognition**

The Foundation reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions.

Donated services are recognized if the services received create or enhance a non-financial asset or require specialized skills provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. When significant, donated securities, materials, equipment and services are reflected as contributions in the accompanying statements at their estimated value at the date of receipt.

# **FRAXA Research Foundation, Inc.**

## **Notes to Financial Statements**

**December 31, 2024**

### **NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued**

Event revenue consists of revenue generated from various fundraising events throughout the year. The primary revenue generated from these events is contribution revenue. However, the Foundation occasionally hosts events requiring a fee for attending.

Other revenue is comprised of consulting income for industry consulting services performed from time to time. The revenue is recognized when services have been provided and completed.

Investment income consists of income, net of losses and investment expenses, generated from the Foundation's investment portfolio. See Note D for additional information on investments.

#### Leases

The Foundation leases the office space on a month-to-month basis at \$550 per month, which is expensed as incurred. Total lease expense was \$6,600 during the year ended December 31, 2024. The Foundation has no long-term leases to report under ASC842 – Leases. During the year ended December 31, 2024 the Foundation did not have to pay a lease for two months due to construction that occurred during the year.

Net assets with donor restrictions that are released from restriction in the same year received are recorded as net assets without donor restriction. The Foundation did not have any board designated funds during 2024.

#### Net Assets

The Foundation classifies net assets, revenues, gains and losses based on the existence or absence of donor or grantor-imposed restrictions. Consequently, net assets and changes therein are classified and reported as follows:

- Net assets without donor restrictions represent the portion of net assets available for use in general operations and not subject to donor or certain grantor restrictions. Additionally, gains and investment income are treated as unrestricted revenue unless specifically restricted by the donor or by law.
- Net assets with donor restrictions represent the portion of net assets subject to donor or certain grantor-imposed restrictions. Certain donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates resources to be maintained in perpetuity. Donor-imposed restrictions are released and are reclassified to net assets without donor restrictions when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resources were restricted has been fulfilled, or both.

As of December 31, 2024, the Foundation had net assets with donor restrictions in the amount of \$196,088.

#### Donated Assets

From time to time the Foundation receives donated assets and are recorded as contributions in the financial statements. For the year ended December 31, 2024, the Foundation received donated subscriptions in the amount of \$5,256.

#### Allocation of Expenses

The financial statements report certain categories of expenses that are attributable to more than one program or supporting function. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include compensation and benefits, which are allocated on the basis of estimates of time and effort, as well as occupancy, which is allocated on a square footage basis. General and administrative expenses include those expenses that are not directly identifiable with any other specific function but provide for the overall support and direction of the Foundation.

# FRAXA Research Foundation, Inc.

## Notes to Financial Statements

December 31, 2024

### NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued

#### Advertising Costs

Advertising costs are expensed as incurred. For the year ended December 31, 2024, there were no advertising expenses.

#### Use of Estimates

Management uses estimates and assumptions in preparing financial statements in accordance with U.S. generally accepted accounting principles. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used.

#### Subsequent Events

Subsequent events have been evaluated through August 5, 2025, which is the date the financial statements were available to be issued.

### NOTE B – CONCENTRATIONS OF RISK

The Foundation maintains its cash balances in several financial institutions. The FDIC insures balances up to \$250,000. As of December 31, 2024, the Foundation maintained \$3,047,330 of its total cash and certificates of deposit, excluding reconciling items, in banks that carry additional insurance through the Depositors Insurance Fund (DIF). DIF is a private, industry-sponsored insurance fund that insures all deposits above Federal Deposit Insurance Corporation limits at Massachusetts chartered savings banks. The Foundation's remaining cash balance at December 31, 2024 was within insurable limits with either the FDIC or Securities Investor Protection Corporation (SIPC). However, those accounts could from time to time exceed insurable limits.

The Foundation also maintains significant investments in securities which are subject to potential uninsured market losses.

### NOTE C – LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS

The following reflects the Foundation's financial assets as of the statement of financial position date, reduced by amounts not available for general use because of contractual or donor-imposed restrictions within one year of the balance sheet date. As of December 31, 2024, all donor-restricted amounts are available for use within one year for their restricted purpose.

Financial assets at year-end (all current assets except prepaid expenses):	\$4,964,245
Less those unavailable for general expenditures within one year:	<u>-</u>
Financial assets available to meet cash needs for general expenditure within one year:	<u>\$4,964,245</u>

As part of the Foundation's liquidity management, it periodically invests cash in excess of estimated budgetary needs in its investment accounts. As of December 31, 2024, the Foundation did not have any borrowing commitments.

### NOTE D – INVESTMENTS AND FAIR VALUE MEASUREMENTS

Management has adopted the criteria of Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 820, (formerly SFAS No. 157, "*Fair Value Measurements*"). FASB ASC 820 defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles, and expands disclosure about fair value measurements. FASB ASC 820 establishes a fair value framework that prioritizes the inputs and assumptions used to measure fair value. The three levels of the fair value framework under FASB ASC 820 are as follows:

**FRAXA Research Foundation, Inc.**

Notes to Financial Statements

December 31, 2024

**NOTE D – INVESTMENTS AND FAIR VALUE MEASUREMENTS, continued**

Level 1 – Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs other than quoted market prices in active markets that are observable for the asset either directly or indirectly, including inputs in markets that are not considered to be active.

Level 3 – Inputs that are unobservable.

An asset or liability's level within the framework is based upon the lowest level of any input that is significant to the fair value measurement. At December 31, 2024, fair values of investments and cash were all measured on a recurring basis using level 1 of the hierarchy and certificates of deposit were measured on a recurring basis using level 2 of the hierarchy.

Net appreciation in the fair value of investments, which consist of the realized gains and losses and the unrealized appreciation (decline) of those investments, is shown in the statement of activities. During 2024, the Foundation received donated stock with a total fair market value of \$200,817 at the date of contribution. The fair value of stocks received as donations are recorded to contribution revenue when received.

The fair market value of these stocks at December 31, 2024, if not sold during the year, is included in the total investments at year end. The following is a summary of investments and certificates of deposit as of December 31, 2024:

<u>Description</u>	<u>Cost</u>	<u>Fair Market Value</u>	<u>Cumulative Unrealized Gain</u>
StockCross – Equities/Options	\$ 225,636	\$ 225,903	\$ 267
StockCross – Mutual Funds	70,688	90,317	19,629
CIBC – Fixed Income	665,893	668,898	3,005
CIBC – Real Assets	25,400	35,682	10,282
CIBC – Equities	605,276	769,312	164,036
	<u>\$1,592,893</u>	<u>\$1,790,112</u>	<u>\$ 197,219</u>

  

<u>Description</u>	<u>Cost</u>	<u>Fair Market Value</u>	<u>Cumulative Unrealized Gain</u>
Certificates of Deposit	\$ 688,866	\$ 688,866	\$ -

Investment income reported on the statement of activities includes interest, dividends and capital gain distributions, net of investment fees. Investment fees during the year ended December 31, 2024 totaled \$7,059.

**NOTE E – RELATED PARTY TRANSACTIONS**

There were no reportable related party transactions.

**FRAXA Research Foundation, Inc.**

Notes to Financial Statements

December 31, 2024

**NOTE F – INCOME TAX STATUS**

The Foundation is organized and operated exclusively for charitable purposes. Income related to its charitable purpose is exempt from federal and state income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code.

The Foundation has adopted the application of the provisions of FASB ASC 740-10 (formerly FASB Interpretation No. 48, “*Accounting For Uncertainty in Income Taxes*”). The primary tax positions made by the Organization are the existence/non-existence of Unrelated Business Income Tax and the Organization’s status as an exempt organization under Section 501(c)(3) of the Internal Revenue Code. The Foundation currently evaluates all tax positions and makes determinations regarding the likelihood of those positions being upheld under review. For the year presented, and as a result of adoption, the Foundation has not recognized any tax benefits or loss contingencies for uncertain tax positions based on its evaluations. The Foundation's Form 990, *Return of Organization Exempt from Income Tax*, for the years ending December 31, 2021 through 2024 are subject to examination by the IRS, generally for 3 years after it is filed.

**NOTE G – GRANTS ISSUED**

The Foundation issues various grants to outside researchers as part of its program activities. The Foundation records grant expense when the grant is approved and issued as it considers the majority of grant conditions met at the time of approval. Occasionally, the full amount of grant funds are not fully utilized by the researcher prior to the grant deadline and the unused portion of the grant is returned to the Foundation. These amounts are typically immaterial and rarely occur. Any grant funds returned are netted with grant expense. There were no funds returned during the year ended December 31, 2024.